Organon & Co

$30.97 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Organon & Co

Organon & Co. is a science-based global pharmaceutical company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. Its women's health portfolio includes Nexplanon or Implanon NXT, which is a patented long-acting reversible contraceptive. Its operating segments include the Organon Products segment. The Organon Products segment is engaged in developing and delivering health solutions through its portfolio of prescription therapies within women’s health, biosimilars, and established brands. The Company's products segment portfolio includes: Women’s Health, Biosimilars and Established Brands. Women’s Health contains contraception and fertility brands, such as Nexplanon or Implanon NXT, NuvaRing and elonva. The Company's Biosimilars portfolio consists of three immunology products: Brenzys, Renflexis and Hadlima; and two oncology products: Ontruzant and Aybintio.

Stock Analysis

last close $31.82
1-mo return 8.4%
3-mo return -11%
avg daily vol. 1.66M
52-week high 38.75
52-week low 27.25
market cap. $8.3B
forward pe 5.5
annual div. 1.12
roe 34.5%
ltg forecast -
dividend yield 3.52%
annual rev. $8.1B
inst own. 69%
baraka

Subscribe now for daily local and international financial news

Subscribe